Gansu Cancer Hospital
13
6
6
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
15%
2 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Role: collaborator
Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms
Role: collaborator
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
Role: collaborator
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Role: collaborator
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Role: collaborator
Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer
Role: collaborator
Genotype-guided Treatment in DLBCL
Role: collaborator
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
Role: collaborator
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
Role: collaborator
The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
Role: collaborator
Application of Deep-learning and Ultrasound Elastography in Opportunistic Screening of Breast Cancer
Role: collaborator
Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy
Role: collaborator
Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
Role: collaborator
All 13 trials loaded